

# Clinical trials of LCZ696

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 hypertension

Trial	Treatments	Patients	Trials design and methods
<b>LCZ696 vs placebo</b>			
<a href="#">Ruilope , 2010</a> n=NA follow-up: 8 weeks	LCZ696 for 8 weeks versus placebo	patients with mild to moderate hypertension	Parallel groups double blind 18 countries

More details and results :

- anti hypertensive agents for hypertension in all type of patient at <http://www.trialresultscenter.org/go-Q13>
- angiotensin-receptor blockers for hypertension in all diseases requiring ACEi (HF, CHD, HT,...) at <http://www.trialresultscenter.org/go-Q125>
- anti hypertensive agents for hypertension in uncomplicated hypertension at <http://www.trialresultscenter.org/go-Q685>

## References

### Ruilope, 2010:

Ruilope LM, Dukat A, Bhm M, Lacourcire Y, Gong J, Lefkowitz MP Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010 Mar 15;: [20236700] [10.1016/S0140-6736\(09\)61966-8](https://doi.org/10.1016/S0140-6736(09)61966-8)

## 2 heart failure

Trial	Treatments	Patients	Trials design and methods
<b>LCZ696 vs Valsartan</b>			
<a href="#">PARAGON-HF</a> <i>ongoing</i> [NCT01920711] n=4600 follow-up:	LCZ696 target dose 200mg bid versus Valsartan target dose of 160 mg b.i.d.	patients with HF with preserved ejection fraction	d

More details and results :

- angiotensin-receptor blockers for heart failure in patients with preserved-LVEF heart failure at <http://www.trialresultscenter.org/go-Q233>

## References

### PARAGON-HF, :

ongoing trial NCT01920711

Rossi A, Gheorghiadu M, Triposkiadis F, Solomon SD, Pieske B, Butler J Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. *Circ Heart Fail* 2014 Nov;7:1042-9 [25415957] [10.1161/CIRCHEARTFAILURE.114.001276](https://doi.org/10.1161/CIRCHEARTFAILURE.114.001276)

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. *JACC Heart Fail* 2017;5:471-482 [28662936]

## 3 miscellaneous

Trial	Treatments	Patients	Trials design and methods
<b>LCZ696 vs placebo</b>			
<a href="#">Ruilope, 2010</a> n=NA follow-up: 8 weeks	LCZ696 for 8 weeks versus placebo	patients with mild to moderate hypertension	Parallel groups double blind 18 countries

More details and results :

- angiotensin-receptor blockers for miscellaneous in all type of patients at <http://www.trialresultscenter.org/go-Q425>

## References

### Ruilope, 2010:

Ruilope LM, Dukat A, Bhm M, Lacourciere Y, Gong J, Lefkowitz MP Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. *Lancet* 2010 Mar 15;: [20236700] [10.1016/S0140-6736\(09\)61966-8](https://doi.org/10.1016/S0140-6736(09)61966-8)

## 4 patients at high risk for cardiovascular events

Trial	Treatments	Patients	Trials design and methods
<b>LCZ696 vs placebo</b>			
Ruilope , 2010 n=NA follow-up: 8 weeks	LCZ696 for 8 weeks versus placebo	patients with mild to moderate hypertension	Parallel groups double blind 18 countries

More details and results :

- angiotensin-receptor blockers for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q97>

## References

### Ruilope, 2010:

Ruilope LM, Dukat A, Bhm M, Lacourcire Y, Gong J, Lefkowitz MP Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010 Mar 15; [20236700] 10.1016/S0140-6736(09)61966-8

## 5 heart failure with preserved LVEF

Trial	Treatments	Patients	Trials design and methods
<b>LCZ696 vs valsartan</b>			
PARAMOUNT , 2012 [NCT00887588] n=149/152 follow-up: 12 weeks	LCZ696 titrated to 200 mg twice daily for 36 weeks versus valsartan titrated to 160 mg twice daily,	-	double-blind
PARAGON-HF <i>ongoing</i> [NCT01920711] n=4600 follow-up:	LCZ696 target dose 200mg bid versus Valsartan target dose of 160 mg b.i.d.	patients with HF with preserved ejection fraction	d

More details and results :

- All mechanism for heart failure with preserved LVEF in all type of patients at <http://www.trialresultscenter.org/go-Q237>

## References

### PARAMOUNT, 2012:

Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. *Eur J Heart Fail* 2014;16:671-7 [24692284]

Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet* 2012;380:1387-95 [22932717]

**PARAGON-HF, :**

ongoing trial NCT01920711

Rossi A, Gheorghide M, Triposkiadis F, Solomon SD, Pieske B, Butler J Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. *Circ Heart Fail* 2014 Nov;7:1042-9 [25415957] [10.1161/CIRCHEARTFAILURE.114.001276](#)

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. *JACC Heart Fail* 2017;5:471-482 [28662936]